Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
Li J, Wen WX, Eklund M, Kvist A, Eriksson M, Christensen HN, Torstensson A, Bajalica-Lagercrantz S, Dunning AM, Decker B, Allen J, Luccarini C, Pooley K, Simard J, Dorling L, Easton DF, Teo SH, Hall P, Borg Å, Grönberg H, Czene K. Li J, et al. Int J Cancer. 2019 Mar 1;144(5):1195-1204. doi: 10.1002/ijc.31841. Epub 2018 Nov 9. Int J Cancer. 2019. PMID: 30175445 Free PMC article.
Prediction of breast cancer risk for sisters of women attending screening.
Mao X, He W, Eriksson M, Lindström LS, Holowko N, Bajalica-Lagercrantz S, Hammarström M, Grassmann F, Humphreys K, Easton D, Hall P, Czene K. Mao X, et al. Among authors: bajalica lagercrantz s. J Natl Cancer Inst. 2023 Nov 8;115(11):1310-1317. doi: 10.1093/jnci/djad101. J Natl Cancer Inst. 2023. PMID: 37243694 Free PMC article.
Investigation of Genetic Alterations Associated With Interval Breast Cancer.
Rodriguez J, Grassmann F, Xiao Q, Eriksson M, Mao X, Bajalica-Lagercrantz S, Hall P, Czene K. Rodriguez J, et al. Among authors: bajalica lagercrantz s. JAMA Oncol. 2024 Mar 1;10(3):372-379. doi: 10.1001/jamaoncol.2023.6287. JAMA Oncol. 2024. PMID: 38270937 Free PMC article.
Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study.
Omran M, Johansson H, Lundgren C, Silander G, Stenmark-Askmalm M, Loman N, Baan A, Adra J, Kuchinskaya E, Blomqvist L, Tham E, Bajalica-Lagercrantz S, Brandberg Y; Swedish Clinical TP53 Study Group (SweClinTP53). Omran M, et al. Among authors: bajalica lagercrantz s. Cancer. 2023 Mar 15;129(6):946-955. doi: 10.1002/cncr.34631. Epub 2023 Jan 5. Cancer. 2023. PMID: 36601958 Free article.
30 results